Ascendis Health Limited (JSE:ASC)
South Africa · Delayed Price · Currency is ZAR · Price in ZAc 92.00
0.00 (0.00%)
Inactive · Last trade price on Nov 28, 2025
Ascendis Health Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
575.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | 1.47B | -63.39M | -4.13% |
| Jun 30, 2023 | 1.54B | -24.02M | -1.54% |
| Jun 30, 2022 | 1.56B | -266.01M | -14.57% |
| Jun 30, 2021 | 1.83B | -377.56M | -17.14% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Ascendis Health News
- 4 days ago - Ascendis, BioMarin Enter Global Settlement, License Deal For YUVIWEL; Ascendis Stock Up - Nasdaq
- 2 months ago - Ascendis Presents Pivotal ApproACH And Phase 2 COACH Trial Data In Achondroplasia At ICCBH 2026 - Nasdaq
- 3 months ago - Ascendis (ASND) Q1 2026 Earnings Call Transcript - The Motley Fool
- 6 months ago - Ascendis Wins FDA Approval For Rare Disease Therapy - Benzinga
- 6 months ago - Ascendis (ASND) Q4 2025 Earnings Call Transcript - The Motley Fool
- 7 months ago - Ascendis Confirms Durable Growth Benefits In Achondroplasia In COACH Trial - Nasdaq
- 9 months ago - Ascendis (ASND) Q3 2025 Earnings Call Transcript - The Motley Fool
- 1 year ago - Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 ... - GuruFocus